FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington, D.C.	20549	
STATEMENT C	OF CHANGES IN B	BENEFICIAL	OWNERSHIP

	OMB APPRO	DVAL						
	OMB Number:	3235-0287						
l	Estimated average burden							
l	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Geary Richard S</u>					2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ISIS]								neck all appli Directo	cable) or	10% Owner				
PHARMA	CEUTICALS, I	` ,			3. Date of Earliest Transaction (Month/Day/Year) 12/20/2011								helow)	below) below) Senior Vice President					
(Street) CARLSBAD CA 92010				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(S	ate)	(Zip)											. 5.55						
		le I - No			_				Dis	_			_						
Da			Date	ate		Execution Date,		Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4		tr. 3, 4 and	Securition Benefici Owned I Reporte	es ially Following d	Form (D) or	: Direct 0 Indirect 1 Str. 4) 0	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(D)	File	(Instr. 3	and 4)					
										 '			5,278		D				
				6/2011				+		1 '			79 4,278		⁷ 8 D				
				9/2011		12/19/2011				118(1	118 ⁽¹⁾ A		.8 4,396		96 D				
Common Stock			12/19	9/2011		12/19/2011		S ⁽¹⁾				\$6.9	4,278		78 D				
Common Stock				/2011		12/19/2011		-		982(1	982 ⁽¹⁾ A		3 5,260			D			
Common Stock 12/19						S ⁽¹⁾				\$6.8	,								
Common Stock 12/20/				/2011			M ⁽¹⁾		 		\$5.8	5,	5,778		D				
Common Stock 12/20				2011 12/20/201		0/2011	S ⁽¹⁾		1				4,278		D				
Stock			12/20	2011 12/20/201		0/2011	M ⁽¹⁾		-		\$5.8				D				
Common Stock 12/20/2				/2011 12/20/2011		S ⁽¹⁾		300(1)		\$6.9	92 4,278			D					
	T												/ Owned						
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Date,	Transact Code (In		of Deri Secu Acqu (A) o Disp of (E	5. Number of G. Date Expiratior (Month/Date Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date (Month/Day/Year) Amount of Securitie Underlyin Derivativ		f g Security	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following Reported	s S Illy	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code \	,	(A)	(D)				Title	Amount or Number of Shares							
\$5.8	12/16/2011	12/16/2	011	M			1,000	01/03/200	9 (01/02/2012	Common Stock	1,000	\$0	4,044		D			
\$5.8	12/19/2011	12/19/2	011	M			1,100	01/03/200	9 (01/02/2012	Common Stock	1,100	\$0	2,944		D			
\$5.8	12/20/2011	12/20/2	011	М			1,800	01/03/200	9 (01/02/2012	Common Stock	1,800	\$0	1,144		D			
	Stock	Richard S (First) SPHARMACEUTICALS, I ZELLE COURT BAD CA (State) Tab Security (Instr. 3) Stock S	Richard S (First) (Middle) PHARMACEUTICALS, INC. ZELLE COURT BAD CA 92010 (State) (Zip) Table I - Nor Security (Instr. 3) Stock	Conversion or Executive Stock 12/19 Stock 12/20 St	Stock 12/16/2011 Stock 12/20/2011 Stock	Stock 12/16/2011 Stock 12/19/2011 Stock 12/20/2011 Stock	Sinchard S CFirst CFirst CFirst CFirst CFirst CFIPS CF	Siss PHARMACE PHARMACEUTICALS, INC.	Stock 12/19/2011 12/19/20	Sichard S Sich	Sichard S Sich	Sinck 12/16/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/19/2011 12/20/20	SIS PHARMACEUTICALS INC ISIS	SISS PHARMACEUTICALS INC ISIS Concession Month/Day/Year) Sister Concession Month/Day/Year) Mon	Security (Instr. 3)	Size Control Control	Circle Discription Control Discription Discripti		

Explanation of Responses:

Remarks:

^{1.} Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/12. The purchase and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/3/09.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.